Top 10 Immunoprecipitation Companies

Why Immunoprecipitation Market Are Expanding?

The Immunoprecipitation Market is experiencing consistent and robust growth, valued at USD 2.241 billion in 2024 and projected to reach USD 4.128 billion by 2035, registering a CAGR of 5.71% over the 2025-2035 forecast period. According to Market Research Future (MRFR), the market is growing at a rapid pace due to two main demand vectors. First is the increase in global acceptance of proteomics-based drug discovery workflows.

Second is the ever-increasing load of non-communicable diseases that need the use of advanced molecular biology tools for biomarker discovery and validation of therapeutic targets. The WHO reports that non-communicable diseases kill 41 million people every year (74% of all deaths globally) and the CDC reports over 1.9 million new cancer cases in the US in 2023 alone, directly reinforcing institutional demand for protein-level analytical tools like immunoprecipitation.

Therapeutic applications are the largest application category, accounting for 62% of market revenue in 2024, owing to the targeted therapeutic development projects spanning the fields of oncology, autoimmune illness, and rare genetic disorders. Antibodies accounted for 48% of the product market, driven by their use in over 3,000 current clinical biomarker-based research projects worldwide. The Co-Immunoprecipitation (Co-IP) methodology accounts for 57% of the share by technology and is the industry-standard method for protein-protein interaction research. Academic and research institutes account for 55% end-use income, driven by world R&D spend on life sciences expanding at 5%+ each annum.

North America dominated the market with over 45% worldwide revenue share in 2024 and revenue of around USD 1.01 billion, owing to strong NIH funding cycles, high prevalence of chronic diseases, and concentration of biopharmaceutical R&D infrastructure. Europe took a 30% share at USD 0.67 billion, buoyed by Horizon Europe funding and strong university proteomics projects.

Institutional investment in immunoprecipitation-based discovery workflows has been further supported by enhanced NIH appropriations and FDA recommendations on biomarker-driven medication approval paths in 2025-2026. MRFR sees the intersection of proteomics, precision medicine, and biologics development resulting in considerably above-average market growth through the 2030s.

Why Are These Companies Leading the Market?

According to MRFR, category leaders in the Immunoprecipitation Market are differentiated by four structural reasons: breadth of product portfolio including antibodies, kits and magnetic bead systems; technology differentiation through proprietary affinity chemistry and validated protocols; geographic distribution across key research-intensive regions; and M&A strategy to consolidate adjacent protein biology capabilities.

The breadth of the portfolio characterizes market leaders. With our Pierce and Dynabeads product lines, Thermo Fisher Scientific offers one of the most extensive immunoprecipitation ecosystems in the world. Cell Signaling Technology is an example of technology differentiation, with phospho-specific antibodies that are approved for IP and ChIP applications and are used by major oncology research programs.

Merck KGaA (MilliporeSigma) has a structural advantage in terms of geographic reach, supplying IP reagents and ChIP kits in 66 countries. Following the completion of its acquisition in December 2023 for USD 5.7 billion (official Danaher press release), Abcam plc has expanded its recombinant antibody portfolio within Danaher’s life sciences platform, providing global customers with faster access to high-specificity IP-grade antibodies.

According to MRFR, a leader in the Immunoprecipitation Market is identified as someone who can provide a single commercial relationship to a validated end-to-end protein isolation ecosystem, from sample preparation and antibody selection to magnetic bead capture, washing and downstream analysis compatibility.

Top 10 Global Immunoprecipitation Companies - MRFR Rankings (2026)

MRFR has identified and profiled the following leading immunoprecipitation companies globally, evaluated on the basis of revenue performance, market capitalization, geographic presence, product breadth, innovation strategy, and client base.

Rankings based on MRFR analysis. Revenue figures sourced from official company filings and investor relations disclosures. Merck KGaA FY2024 group revenue confirmed at EUR 21.2B (source: Merck KGaA Q4 2024 earnings release, March 6, 2025). Bio-Techne FY2024 revenue confirmed at USD 1.2B (source: Bio-Techne Q4 FY2024 earnings release, August 7, 2024). Abcam acquisition value corrected to USD 5.7B (source: Danaher official press release, August 28, 2023; completion confirmed December 6, 2023). CAGR reflects company-guided or analyst-estimated growth for life sciences/relevant segments.

Detailed Company Profiles

1. Thermo Fisher Scientific | NYSE: TMO | Waltham, Massachusetts, USA

Company Overview. Thermo Fisher Scientific is the world leader in the immunoprecipitation market, providing complete protein isolation solutions through its Pierce Protein Biology and Dynabeads product lines, which cover classical IP, Co-IP, ChIP, and RNA-IP workflows for academic, pharmaceutical and clinical research customers. Pierce Immunoprecipitation kits combine antibody conjugation, magnetic bead capture, and improved wash steps to save hands-on time by as much as 60% compared to manual IP procedures. Thermo Fisher serves customers in 180 countries, with a significant presence in oncology research, pharmaceuticals, antibody development and academic proteomics programs. Total corporate sales for FY2024 were USD 42.88 billion (as per the official Q4 2024 results release, January 30, 2025), and it is the world's largest life science products and services provider.

2. Merck KGaA (MilliporeSigma) | XETRA: MRK | Darmstadt, Germany

Company Overview. Merck KGaA is a competitor in the immunoprecipitation market with its MilliporeSigma life science business, providing a broad array of Protein A/G agarose beads, ChIP-grade antibodies, IP lysis buffers and validated ChIP-seq and Co-IP reagent kits utilized in pharmaceutical, academic and clinical laboratory research globally. Merck KGaA has a commercial infrastructure for the life sciences that serves customers in 66 countries. In FY2024, total group sales were EUR 21.2 billion (Merck KGaA Q4 2024 results release, March 6, 2025), with organic growth of 2.0% and Life Science returning to growth in the second half of the year.

3. Bio-Rad Laboratories | NYSE: BIO | Hercules, California, USA

Company Overview. Bio-Rad Laboratories addresses the immunoprecipitation market through its protein interaction assay portfolio, including SureBeads Magnetic Beads for antibody capture, IP-validated antibodies, and seamless integration with its western blot and qPCR downstream analysis systems. The company serves more than 100,000 research laboratories across 70 countries. Total company revenue for FY2024 was USD 2.57 billion (per Bio-Rad Q4 2024 earnings release, February 13, 2025), with the Life Science segment contributing USD 1.028 billion.

4. Abcam plc (Danaher) | Cambridge, United Kingdom

Company Overview. In December 2023, Danaher Corporation acquired Abcam plc, a specialist supplier of IP-grade and ChIP-grade recombinant antibodies for USD 5.7 billion (total enterprise value per Danaher official press release, August 28, 2023 and acquisition completion announcement, December 6, 2023). Abcam’s recombinant antibody technology provides lot-to-lot consistency, which is essential for reproducible ChIP-seq and Co-IP investigations. The company has customers in more than 130 countries.

5. Cell Signaling Technology (CST) | Private | Danvers, Massachusetts, USA

Company Overview. Cell Signaling Technology is a privately held premium antibody manufacturer whose phospho-specific and modification-state antibodies validated for immunoprecipitation and ChIP applications are considered the reference standard in cell signaling research globally. CST’s SimpleChIP Enzymatic Chromatin IP Kit is among the most widely cited ChIP protocols in peer-reviewed literature. The company serves approximately 50 countries, with a concentrated academic and biopharmaceutical customer base across the United States, Europe, and Japan. CST’s estimated revenue exceeds USD 400 million, with consistent growth driven by expanding antibody validation breadth.

6. Santa Cruz Biotechnology | Private | Dallas, Texas, USA

Company Overview. Santa Cruz Biotechnology is one of the world’s largest dedicated antibody suppliers, maintaining a catalog of over 20,000 IP-grade antibodies alongside Protein A/G agarose, IP lysis buffers, and negative control IP reagents. The company’s product breadth covers virtually every human protein target relevant to immunoprecipitation-based protein interaction studies. Santa Cruz Biotechnology distributes through 40+ countries and serves over 50,000 active research customers.

7. Sigma-Aldrich (Merck Group) | Part of Merck KGaA | St. Louis, Missouri, USA

Company Overview. Sigma-Aldrich, the life science division of Merck KGaA’s commercial brand in North America, provides a variety of immunoprecipitation reagents including Protein A/G magnetic beads, EZview affinity gels, IP lysis buffers, crosslinkers and elution reagents in standard IP protocols used at leading research institutions in 160 countries. The brand is the main supplier of IP reagents to US academic institutions and pharmaceutical research facilities.

8. R&D Systems (Bio-Techne) | NASDAQ: TECH | Minneapolis, Minnesota, USA

Company Overview. R&D Systems, a brand of Bio-Techne Corporation, supplies IP-validated antibodies, Protein G magnetic particles, and RNA Immunoprecipitation (RIP) kits serving proteomics and epitranscriptomics researchers across 45+ countries. Bio-Techne’s total revenue reached USD 1.2 billion in FY2024 (fiscal year ending June 30, 2024; per Bio-Techne Q4 FY2024 earnings release, August 7, 2024), with its Protein Sciences segment contributing the majority of revenue.

9. Takara Bio Inc. | TSE: 4974 | Kusatsu, Shiga, Japan

Company Overview. Takara Bio is a Japan-based life science tools company that participates in the immunoprecipitation market through its Chromatin IP, Co-IP, and RNA Immunoprecipitation kit portfolio, serving academic and pharmaceutical research customers across 30+ countries with a concentration in Asia-Pacific. The company’s integrated approach combines IP capture reagents with downstream NGS library preparation kits. Takara Bio’s estimated revenue exceeds USD 350 million, with consistent growth driven by NGS-adjacent research tool demand.

10. Active Motif | Private | Carlsbad, California, USA

Company Overview. Active Motif is a specialist firm in epigenetics and chromatin biology tools, competing in the immunoprecipitation market with its CUTANA ChIP and CUT&RUN product lines, as well as ChIP-grade antibodies, RIP kits and DRIP-seq reagents. The company has customers in ~25 countries, with a heavy concentration in academic epigenomics institutions, cancer research institutes and pharmaceutical epigenetics initiatives. Active Motif’s expected revenue stands in the range of USD 50-100 million.

M&A Activity Tracker (2022-2026)

The Immunoprecipitation Market has seen massive consolidation as large life science instrument businesses look for inorganic growth to fill capability shortages. Market Research Future keeps an eye on the following verified transactions related to the immunoprecipitation market. Note: The initial post mistakenly stated Bio-Techne’s acquisition of ProteinSimple as a 2021 deal valued at USD 963M; confirmed sources reveal it was a 2014 acquisition for USD 300 million. The Danaher purchase of Abcam has been validated at $5.7B enterprise value, revised from $5.9B.

Key Trend. MRFR analysis identifies antibody portfolio consolidation and workflow integration as the dominant M&A themes, with acquirers prioritizing validated IP-grade recombinant antibody catalogs and downstream NGS compatibility assets that accelerate end-to-end protein isolation and characterization capabilities for pharmaceutical R&D customers.

R&D Investment & Innovation Signals

R&D investment across the Immunoprecipitation Market has increased materially in 2025-2026 as vendors race to develop lower-input, higher-specificity IP workflow solutions. Market Research Future tracks the following 2025-2026 R&D and technology programs from official company sources:

• Thermo Fisher Scientific advanced its Dynabeads surface chemistry platform in 2025, engineering high-density streptavidin and Protein G coatings on superparamagnetic particles to achieve 40% higher antibody loading capacity for low-abundance target IP applications in clinical proteomics programs.
• Merck KGaA (MilliporeSigma) launched optimized ChIP lysis buffers in 2025 that maintain chromatin integrity across a wider range of cell types, enabling ChIP-seq workflows for previously inaccessible primary cell populations including circulating tumor cells and bone marrow aspirates.
• Cell Signaling Technology invested in expanding its phospho-proteome antibody validation program in 2025, adding IP-validated antibodies for 200+ post-translational modification sites across metabolic enzyme and kinase families critical to precision oncology target identification.
• Bio-Rad Laboratories integrated its SureBeads Magnetic IP platform with its CFX Real-Time PCR system in 2025, enabling ChIP-qPCR workflows with automated magnetic separation steps that reduce hands-on time by 50% in high-throughput epigenomics screening.
• Abcam (Danaher) deployed AI-assisted antibody validation algorithms in 2025, using machine learning to predict antibody cross-reactivity in IP applications and prioritize validation resources toward highest-specificity clones for new target proteins in immuno-oncology.
• Takara Bio invested in developing a combined ChIP-seq and ATAC-seq co-precipitation workflow kit in 2025, enabling simultaneous profiling of histone modifications and chromatin accessibility from a single IP experiment on limited clinical samples.
• Active Motif advanced its CUTANA platform with a pA-MNase Series 3 enzyme that achieves consistent cleavage efficiency across heterochromatic regions and G-quadruplex DNA structures, enabling transcription factor ChIP from previously recalcitrant genomic contexts.
• R&D Systems (Bio-Techne) launched m6A reader protein IP antibody panels in 2025, enabling RNA immunoprecipitation-based profiling of epitranscriptomic regulatory complexes in cancer cell lines and patient-derived organoids.